Dexcom (Nasdaq:DXCM) announced today that it broke ground on a new state-of-the-art manufacturing facility in Ireland. The San Diego-based continuous glucose monitor (CGM) maker announced plans to invest $325 million in Athenry last May. Breaking ground on the facility marks the first steps toward bringing more than 1,000 jobs to the area. The company expects […]
Dexcom
How Dexcom designed a new ‘life-changing’ sensor for even more people with diabetes
Dexcom (Nasdaq:DXCM) Chair, President and CEO Kevin Sayer says that, in 2019, he gave a speech announcing the company’s first $1 billion year. This week, Sayer announced the continuous glucose monitor maker’s first $1 billion quarter. Plenty of innovation has bolstered that progress over the past few years. Nearly one year ago, Dexcom launched its […]
Dexcom submits new glucose sensor to FDA, expects launch this summer
Dexcom (Nasdaq:DXCM) announced that it submitted its new Stelo glucose sensor to the FDA for review at the end of last year. The continuous glucose monitor (CGM) maker designed Stelo specifically for people with type 2 diabetes who do not use insulin. San Diego-based Dexcom designed Stelo for a 15-day wear with a cash-pay option. […]
The 10 biggest diabetes tech stories from 2023
It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part. Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too. In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no […]
Beta Bionics integrates iLet bionic pancreas with Dexcom G7
Beta Bionics announced today that it began the U.S. launch of its iLet bionic pancreas with the Dexcom G7 continuous glucose monitor (CGM). The launch marks the second G7-compatible automated insulin delivery system to hit the market in as many days. Yesterday, Tandem Diabetes Care became the first to launch an artificial pancreas using Dexcom’s […]
Tandem Diabetes Care launches first automated insulin pump integrated with Dexcom G7 CGM
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its updated t:slim X2 insulin pump software with the Dexcom (Nasdaq:DXCM) G7. Integration makes Tandem the first to offer automated insulin delivery with the latest-generation Dexcom continuous glucose monitor (CGM). The FDA cleared the next-generation Dexcom G7 in December 2022. By February of this year, the […]
ViCentra launches hybrid closed-loop insulin system with Dexcom G6
ViCentra announced today that it launched a hybrid closed-loop automated insulin delivery system that uses the Dexcom G6 CGM. Utrecht, The Netherlands-based ViCentra designed the system to deliver insulin through its Kaleido insulin pump. The Diabeloop DBLG1 algorithm receives input from Dexcom’s G6 continuous glucose monitor. Together, they form an artificial pancreas offering flexible self […]
Here’s what diabetes tech companies are doing on World Diabetes Day
Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day. World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. In an effort to drive awareness and […]
Dexcom raises awareness on World Diabetes Day
Dexcom (Nasdaq:DXCM) today announced its effort to raise awareness for diabetes technology on World Diabetes Day. The continuous glucose monitor (CGM) maker aims to highlight the need to improve access to diabetes technologies. It follows Abbott and Insulet as companies look to recognize World Diabetes Day and National Diabetes Awareness Month. Dexcom unveiled a first-of-its-kind […]
NICE recommends automated insulin delivery tech rollout in UK, Medtronic, Dexcom applaud
An independent committee of the National Institute for Health and Care Excellence (NICE) voiced support for closed-loop insulin delivery. The UK-based institute recommended offering automated insulin delivery (AID) for people whose type 1 diabetes is not controlled with their current device despite best possible management with an insulin pump or real-time or intermittently scanned continuous […]